Shares of Lixte Biotechnology fell to 4.06 USD after the company’s plan to allocate 25% of reserves to a Bitcoin treasury. Conversely, Ethereum treasury firms are thriving, showing significant gains driven by the recent strong performance of ETH.
Traders are increasingly favoring Ethereum over Bitcoin, as ETH is viewed as better positioned for growth. With potential interest rate cuts anticipated from the Federal Reserve, this shift is likely to impact stock prices positively.
Leave a Reply